Paul A Gastañaduy1, Ingrid Contreras-Roldán2, Chris Bernart2, Beatriz López2, Stephen R Benoit3, Marvin Xuya2, Fredy Muñoz2, Rishi Desai1, Osbourne Quaye4, Ka Ian Tam5, Diana K Evans-Bowen5, Umesh D Parashar6, Manish Patel6, John P McCracken2. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Center for Health Studies, Universidad del Valle de Guatemala. 3. International Emerging Infections Program, Centers for Disease Control and Prevention, Guatemala City. 4. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia West African Center for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon. 5. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: Concerns remain about lower effectiveness and waning immunity of rotavirus vaccines in resource-poor populations. We assessed vaccine effectiveness against rotavirus in Guatemala, where both the monovalent (RV1; 2-dose series) and pentavalent (RV5; 3-dose series) vaccines were introduced in 2010. METHODS: A case-control evaluation was conducted in 4 hospitals from January 2012 to August 2013. Vaccine status was compared between case patients (children with laboratory-confirmed rotavirus diarrhea) and 2 sets of controls: nondiarrhea "hospital" controls (matched by birth date and site) and nonrotavirus "test-negative" diarrhea controls (adjusted for age, birth month/year, and site). Vaccine effectiveness ([1 - odds ratio of vaccination] × 100%) was computed using logistic regression models. RESULTS: We evaluated 213 case patients, 657 hospital controls, and 334 test-negative controls. Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency department visit or hospitalization was 74% (95% confidence interval [CI], 58%-84%) with hospital controls, and 52% (95% CI, 26%-69%) with test-negative controls. Using hospital controls, no significant difference in effectiveness was observed between infants 6-11 months (74% [95% CI, 18%-92%]) and children ≥12 months of age (71% [95% CI, 44%-85%]) (P= .85), nor between complete courses of RV1 (63% [95% CI, 23%-82%]) and RV5 (69% [95% CI, 29%-87%]) (P= .96). An uncommon G12P[8] strain, partially heterotypic to strains in both vaccines, was identified in 89% of cases. CONCLUSIONS: RV1 and RV5 were similarly effective against severe rotavirus diarrhea caused by a heterotypic strain in Guatemala. This supports broader implementation of rotavirus vaccination in low-income countries where >90% global deaths from rotavirus occur. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Concerns remain about lower effectiveness and waning immunity of rotavirus vaccines in resource-poor populations. We assessed vaccine effectiveness against rotavirus in Guatemala, where both the monovalent (RV1; 2-dose series) and pentavalent (RV5; 3-dose series) vaccines were introduced in 2010. METHODS: A case-control evaluation was conducted in 4 hospitals from January 2012 to August 2013. Vaccine status was compared between case patients (children with laboratory-confirmed rotavirus diarrhea) and 2 sets of controls: nondiarrhea "hospital" controls (matched by birth date and site) and nonrotavirus "test-negative" diarrhea controls (adjusted for age, birth month/year, and site). Vaccine effectiveness ([1 - odds ratio of vaccination] × 100%) was computed using logistic regression models. RESULTS: We evaluated 213 case patients, 657 hospital controls, and 334 test-negative controls. Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency department visit or hospitalization was 74% (95% confidence interval [CI], 58%-84%) with hospital controls, and 52% (95% CI, 26%-69%) with test-negative controls. Using hospital controls, no significant difference in effectiveness was observed between infants 6-11 months (74% [95% CI, 18%-92%]) and children ≥12 months of age (71% [95% CI, 44%-85%]) (P= .85), nor between complete courses of RV1 (63% [95% CI, 23%-82%]) and RV5 (69% [95% CI, 29%-87%]) (P= .96). An uncommon G12P[8] strain, partially heterotypic to strains in both vaccines, was identified in 89% of cases. CONCLUSIONS: RV1 and RV5 were similarly effective against severe rotavirus diarrhea caused by a heterotypic strain in Guatemala. This supports broader implementation of rotavirus vaccination in low-income countries where >90% global deaths from rotavirus occur. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Jordan E Cates; Avnika B Amin; Jacqueline E Tate; Ben Lopman; Umesh Parashar Journal: Pediatr Infect Dis J Date: 2021-12-01 Impact factor: 2.129
Authors: Lauren M Schwartz; M Elizabeth Halloran; Ali Rowhani-Rahbar; Kathleen M Neuzil; John C Victor Journal: Vaccine Date: 2016-11-18 Impact factor: 3.641
Authors: K Zaman; David A Sack; Kathleen M Neuzil; Mohammad Yunus; Lawrence H Moulton; Jonathan D Sugimoto; Jessica A Fleming; Ilias Hossain; Shams El Arifeen; Tasnim Azim; Mustafizur Rahman; Kristen D C Lewis; Andrea J Feller; Firdausi Qadri; M Elizabeth Halloran; Alejandro Cravioto; John C Victor Journal: PLoS Med Date: 2017-04-18 Impact factor: 11.069
Authors: Corinne Willame; Marije Vonk Noordegraaf-Schouten; Emilia Gvozdenović; Katrin Kochems; Anouk Oordt-Speets; Nicolas Praet; Rosa van Hoorn; Dominique Rosillon Journal: Open Forum Infect Dis Date: 2018-11-12 Impact factor: 3.835
Authors: Kayoko Shioda; Lucia Helena de Oliveira; Jennifer Sanwogou; Gloria Rey-Benito; Diana Nuñez Azzad; Roxana Elizabeth Castillo; María Liz Gamarra Ramírez; Marta Raquel Von Horoch; Daniel M Weinberger; Virginia E Pitzer Journal: Vaccine Date: 2019-10-28 Impact factor: 4.169